| Small molecule inhibitor of the ileal bile acid transporter being developed by Albireo Pharma, Inc. for the treatment of various cholestatic diseases, including PFIC. |
| Received its first approval on 16 July 2021 in the EU. |
| Approved for the treatment of PFIC in patients aged ≥ 6 months in the EU and for treatment of pruritus in patients aged ≥ 3 months with PFIC in the USA. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.